Table 4.
Median survival and, 1-, 3-year OS of PDAC patients (n = 21,030)
| TNM Stage | Treatments | Median survival | 1-year OS | 3-year OS |
|---|---|---|---|---|
| T1-3N0M0 | Only surgery | 21 | 70.14% | 46.52% |
| Surgery + chemotherapy | 25 | 73.27% | 49.36% | |
| Neoadjuvant radiotherapy | 19 | 67.65% | 39.87% | |
| Adjuvant radiotherapy | 24 | 72.09% | 48.16% | |
| T1-3N + M0 | Only surgery | 10 | 38.65% | 6.88% |
| Surgery + chemotherapy | 15 | 42.27% | 14.85% | |
| Neoadjuvant radiotherapy | 16 | 39.26% | 12.34% | |
| Adjuvant radiotherapy | 19 | 47.64% | 18.63% | |
| T4N0M0 | Only surgery | 7 | 27.14% | 6.72% |
| Surgery + chemotherapy | 17 | 47.67% | 19.36% | |
| Neoadjuvant radiotherapy | 20 | 52.75% | 26.47% | |
| Adjuvant radiotherapy | 14 | 31.82% | 8.73% | |
| T4N + M0 | Only surgery | 6 | 7.28% | 0.05% |
| Surgery + chemotherapy | 10 | 26.18% | 6.54% | |
| Neoadjuvant radiotherapy | 17 | 42.34% | 16.56% | |
| Adjuvant radiotherapy | 16 | 33.29% | 9.86% |
PDAC Pancreatic Ductal Adenocarcinoma, OS Overall Survival